Cost-effectiveness of focal mass drug administration and mass drug administration with dihydroartemisinin-piperaquine for malaria prevention in Southern Province, Zambia: Results of a community-randomized controlled trial

American Journal of Tropical Medicine and Hygiene

Volumn 103, Issue 2, 2020, Pages 46-53

  Yukich, Joshua O ^a   Scott, Callie ^b   Silumbe, Kafula ^c   Larson, Bruce A ^d   Bennett, Adam ^e   Finn, Timothy P ^a   Hamainza, Busiku ^f   Conner, Ruben O ^b   Porter, Travis R ^a   Keating, Joseph ^a   Steketee, Richard W ^b   Eisele, Thomas P ^a   Miller, John M ^c  

^a TULANE UNIVERSITY   (United States)

^b PATH   (United States)

^c PATH MACEPA   (Zambia)

^d BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f MINISTRY OF HEALTH   (Zambia)

Author keywords

[No Author keywords available]

Indexed keywords

DIHYDROARTEMISININ PLUS PIPERAQUINE; ANTIMALARIAL AGENT; ARTEMISININ DERIVATIVE; DIHYDROARTEMISININ; PIPERAQUINE; QUINOLINE DERIVATIVE;

ARTICLE; CLINICAL EFFECTIVENESS; COMMUNICABLE DISEASE CONTROL; COMMUNITY CARE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE TRANSMISSION; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; FOCAL MASS DRUG ADMINISTRATION; HUMAN; MALARIA; MALARIA CONTROL; MASS DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY ANALYSIS; TREATMENT OUTCOME; ZAMBIA; COMBINATION DRUG THERAPY; COST BENEFIT ANALYSIS; DISEASE ERADICATION; DRUG COST; ECONOMICS; HEALTH CARE COST; MALARIA FALCIPARUM; PLASMODIUM FALCIPARUM; PROCEDURES; QUALITY ADJUSTED LIFE YEAR;

ANTIMALARIALS; ARTEMISININS; COST-BENEFIT ANALYSIS; DISEASE ERADICATION; DRUG COSTS; DRUG THERAPY, COMBINATION; HEALTH CARE COSTS; HUMANS; MALARIA, FALCIPARUM; MASS DRUG ADMINISTRATION; PLASMODIUM FALCIPARUM; QUALITY-ADJUSTED LIFE YEARS; QUINOLINES; ZAMBIA;

EID: 85089301653     PISSN: 00029637     EISSN: 14761645     Source Type: Journal    
DOI: 10.4269/ajtmh.19-0661     Document Type: Article

References (34)

1. Chizema-Kawesha E, Miller JM, Steketee RW, Mukonka VM, Mukuka C, Mohamed AD, Miti SK, Campbell CC, 2010. Scaling up malaria control in Zambia: progress and impact 2005-2008. Am J Trop Med Hyg 83: 480-488.
2. Bennett A et al., 2014. A methodological framework for the improved use of routine health system data to evaluate national malaria control programs: evidence from Zambia. Popul Health Metr 12: 30.
3. Bhatt S et al., 2015. The effect of malaria control on Plasmodium falciparum in Africa between 2000 and 2015. Nature 526: 207-211.
4. Steketee RW, Sipilanyambe N, Chimumbwa J, Banda JJ, Mohamed A, Miller J, Basu S, Miti SK, Campbell CC, 2008. National malaria control and scaling up for impact: the Zambia experience through 2006. Am J Trop Med Hyg 79: 45-52.
5. The malERA Refresh Consultative Panel on Combination Interventions and Modelling, 2017. malERA: an updated research agenda for combination interventions and modelling in malaria elimination and eradication. PLoS Med 14: e1002453.
6. World Health Organization Malaria Policy Advisory Committee and Secretariat, 2016. Malaria policy advisory committee to the WHO: conclusions and recommendations of eighth biannual meeting (September 2015). Malar J 15: 117.
7. Zambia Ministry of Health, 2017. National Malaria Elimination Strategic Plan 2017-2021. Lusaka, Zambia: Zambia Ministry of Health.
8. Larsen DA, Bennett A, Silumbe K, Hamainza B, Yukich JO, Keating J, Littrell M, Miller JM, Steketee RW, Eisele TP, 2015. Population-wide malaria testing and treatment with rapid diagnostic tests and artemether-lumefantrine in southern Zambia: a community randomized step-wedge control trial design. Am J Trop Med Hyg 92: 913-921.
9. Eisele TP et al., 2015. Assessing the effectiveness of household-level focal mass drug administration and community-wide mass drug administration for reducing malaria parasite infection prevalence and incidence in Southern Province, Zambia: study protocol for a community randomized controlled trial. Trials 16: 347.
10. Newby G et al., 2015. Review of mass drug administration for malaria and its operational challenges. Am J Trop Med Hyg 93: 125-134.
11. Poirot E, Skarbinski J, Sinclair D, Kachur SP, Slutsker L, Hwang J, 2013. Mass drug administration for malaria. Cochrane Database Syst Rev 2013: CD008846.
12. Husereau D et al.; CHEERS Task Force, 2013. Consolidated health economic evaluation reporting standards (CHEERS) statement. BMJ 346: f1049.
13. Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW, 2015. Methods for the Economic Evaluation of Health Care Programmes. Oxford, United Kingdom: Oxford University Press.
14. Hutton G, Baltussen R, 2005. Cost valuation in resource-poor settings. Health Policy Plan 20: 252-259.
15. OANDA Corporation, 2016. Historical Exchange Rates. Available at: https://www.oanda.com/solutions-for-business/historicalrates-beta/hcc.html. Accessed May 9, 2016 (Online).
16. Bank of Zambia, 2016. Bank of Zambia. Available at: http://www.boz.zm. Accessed May 9, 2016 (Online).
17. U.S. Department of Commerce: Bureau of Economic Analysis, 2016. U.S. Economic Accounts. Available at: http://www.bea.gov/index.htm. Accessed May 9, 2016 (Online).
18. Larson BA, Ngoma T, Silumbe K, Rutagwera MRI, Hamainza B, Winters AM, Miller JM, Scott CA, 2016. A framework for evaluating the costs of malaria elimination interventions: an application to reactive case detection in southern province of Zambia, 2014. Malar J 15: 408.
19. Eisele TP et al., 2016. Short-term impact of mass drug administration with dihydroartemisinin plus piperaquine on malaria in Southern Province Zambia: a cluster-randomized controlled trial. J Infect Dis 214: 1831-1839.
20. Eisele TP et al., 2020. Impact of four rounds of mass drug administration with dihydroartemisinin-piperaquine implemented in Southern Province, Zambia. Am J Trop Med Hyg 103 (Suppl 2): 7-18.
21. WHO, 2014. Choosing Interventions that Are Cost-Effective. Geneva, Switzerland: World Health Organization. Available at: http://www.who.int/choice/en/ (Internet).
22. Keating J, Yukich JO, Mollenkopf S, Tediosi F, 2014. Lymphatic filariasis and onchocerciasis prevention, treatment, and control costs across diverse settings: a systematic review. Acta Trop 135: 86-95.
23. Nonvignon J, Aryeetey GC, Issah S, Ansah P, Malm KL, Ofosu W, Tagoe T, Agyemang SA, Aikins M, 2016. Cost-effectiveness of seasonal malaria chemoprevention in upper west region of Ghana. Malar J 15: 367.
24. Pitt C, Ndiaye M, Conteh L, Sy O, Ba EH, Cissé B, Gomis JF, Gaye O, Ndiaye JL, Milligan PJ, 2017. Large-scale delivery of seasonal malaria chemoprevention to children under 10 in Senegal: an economic analysis. Health Policy Plan 32: 1256-1266.
25. Silumbe K, Yukich JO, Hamainza B, Bennett A, Earle D, Kamuliwo M, Steketee RW, Eisele TP, Miller JM, 2015. Costs and cost-effectiveness of a large-scale mass testing and treatment intervention for malaria in Southern Province, Zambia. Malar J 14: 211.
26. Yukich JO et al., 2008. Costs and consequences of large-scale vector control for malaria. Malar J 7: 258.
27. Woods B, Revill P, Sculpher M, Claxton K, 2016. Country-level cost-effectiveness thresholds: initial estimates and the need for further research. Value Health 19: 929-935.
28. von Seidlein L, Greenwood BM, 2003. Mass administrations of antimalarial drugs. Trends Parasitol 19: 452-460.
29. Payne D, 1988. Did medicated salt hasten the spread of chloroquine resistance in Plasmodium falciparum? Parasitol Today 4: 112-115.
30. Verdrager J, 1986. Epidemiology of emergence and spread of drug-resistant falciparum malaria in southeast Asia. Southeast Asian J Trop Med Public Health 17: 111-118.
31. Institute of Medicine (US) Committee on the economics of antimalarial drugs, 2004. Saving Lives, Buying Time: Economics of Malaria Drugs in an Age of Resistance. Washington, DC: National Academies Press (US).
32. World Health Organization, 2015. Global Reference List of 100 Core Health Indicators, 2015. Available at: https://www.who.int/healthinfo/indicators/2015/chi_2015_33_mortality_ malaria.pdf. Accessed May 5, 2020.
33. World Health Organization, 2018. WHO Methods and Data Sources for Global Burden of Disease Estimates 2000-2016. Available at: https://www.who.int/healthinfo/global_burden_disease/GlobalDALY_method_2000_2016.pdf?ua=1. Accessed May 5, 2020.
34. World Health Organization, 2009. Global Health Risks: Mortality and Burden of Disease Attributable to Selected Major Risks. Available at: https://www.who.int/healthinfo/global_burden_disease/GlobalHealthRisks_report_full.pdf. Accessed May 5, 2020.